Back to results
US 2023/0272000 A1Published application
Saponin purification
AssigneeGlaxosmithkline Biologicals SA
InventorsAhmad Taimour BAIG, Felicie Georgette, Colette DENET, Juan Jose DIAZ GARCIA, Chad Austin FARRENBURG, Lora Lea LAWRENCE, Kent Raymond MYERS, Jeri Kay SANDVICK, Jeb Yeatts VANDENBURG
Life of this patent
Estimating the term…
Abstract
Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.
Claims22
1-79. (canceled)
An adjuvant composition comprising a liposomal formulation comprising a saponin extract;
- the saponin extract comprising at least 93%, in sum and as determined by UV absorbance at 214 nm, of one or more of:
- and 0.25-3%, as determined by UV absorbance at 214 nm, of:
An adjuvant composition comprising a toll-like receptor-4 (TLR4) agonist and a saponin extract;
- the saponin extract comprising at least 93%, in sum and as determined by UV absorbance at 214 nm, of one or more of:
- and 0.25-3%, as determined by UV absorbance at 214 nm, of:
An immunogenic composition comprising:
- a) an adjuvant composition comprising a saponin extract comprising at least 93%, in sum and as determined by UV absorbance at 214 nm, of one or more of:
- and 0.25-3%, as determined by UV absorbance at 214 nm, of:
- and
- b) an immunogen or an antigen, or a polynucleotide encoding the immunogen or the antigen.
1 more element
Dependencies are inferred from the claim text.